NovaThera Ltd. Announces Dr. John Beadle as New Chief Executive Officer
NovaThera has completed a number of pre clinical development studies and is now focusing on moving dermatology and lung therapeutics projects into clinical development. The company is enhancing the management team with development expertise to launch its product development strategy.
Dr Beadle was a co-founder and Chief Medical Officer at PowderMed and he joins NovaThera following the successful sale of that company to Pfizer late in 2006. Prior to PowderMed, Dr Beadle was the Vice President of Product Development at PowderJect and the Vice President of Global Medical Operations at GSK. Dr Beadle said, "I am very excited to join NovaThera, which is working on ambitious plans to develop regenerative medicine products and has a real opportunity to generate good early revenue and grow rapidly in the near future. Longer term NovaThera has a set of technologies that can help to revolutionise medical care in a wide range of therapeutic areas using stem cells to replace and replenish different tissues and organs. I am looking forward to working with the board and the company to make this potential a reality."
Commenting on these developments Michael Anderson, the Chairman of the NovaThera board, said, "We are delighted to have John join NovaThera at this important time for the company which will enable NovaThera to move confidently to the next exciting stage in our development. I would like to thank Gareth for bringing the company to this stage and we are pleased that he will remain with NovaThera to provide his continued expertise and energy." -ends-
Background on NovaThera Ltd
NovaThera Ltd (“NovaThera”) is a spin-out company of Imperial College London. It specialises in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions. NovaThera has a relationship with Imperial College to continue commercialisation of the current and future technologies emanating from world class research groups.
For more information about NovaThera, please visit http://www.novathera.com.